Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis
• To investigate the MRI efficacy of six months' administration of Firategrast in subjects with relapsing-remitting MS
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline
MAJ Il y a 4 ans
A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines
To determine the efficacy of two doses of GSK Biologicals’ HRV vaccine given concomitantly with specific childhood vaccinations against any RV GE caused by the circulating wild-type RV strains during ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Study to Evaluate Mepolizumab Withdrawal After Long-Term Use
To evaluate whether patients with severe eosinophilic asthma who have received longterm treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to receive...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase II, randomized, open, partially controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age
•To evaluate the humoral immune response induced by the H5N1 vaccine candidate in terms of anti-haemagglutinin antibody titer. •To evaluate the safety and reactogenicity of the H5N1 vaccine candidate...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Consumer Healthcare
MAJ Il y a 4 ans
A Proof of Principle Study to Investigate the Efficacy of a Medical Device and Topical Analgesic Combination for the Treatment of Pain and Performance Related Function in Osteoarthritis
The primary objective of this study is to compare the efficacy of 72 hours (hrs) treatment of topical diclofenac plus a heat patch with 72 hrs treatment of topical diclofenac plus a placebo patch on t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Group of Companies
MAJ Il y a 4 ans
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects
The primary objective of this clinical trial is to determine the optimal single dose of oral GW679769 when administered in combination with intravenous (IV) ondansetron hydrochloride for the preventio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to adults aged 66 years and older compared to Fluarix™ administered to adults aged 19-43 years and 66 years and older, who previously participated in the 111737 study
To assess the safety and reactogenicity during the entire study period in subjects aged 66 years or older (previously enrolled in the 111737 study) vaccinated with the FLU NG vaccine or with Fluarix, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase I/II, randomized, observer blinded study to evaluate and compare the safety, reactogenicity and immunogenicity of various formulations of the GlaxoSmithKline Biologicals’ adjuvanted 11-valent pneumococcal conjugate vaccine versus the licensed single-dose 23-valent pneumococcal polysaccharide vaccine and GlaxoSmithKline Biologicals’ aluminium-based 10-valent pneumococcal conjugate vaccine, in healthy elderly subjects
• To assess in healthy elderly subjects the safety and reactogenicity of the 11PCV adjuvanted either with AS01B or AS01E or AS02V, and of the 10-valent pneumococcal conjugate vaccine adjuvanted with A...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Study to test the combination of two new drugs for nine rare cancer types
To determine the ORR of dabrafenib and trametinib anti-cancer combination therapy in subjects with selected rare BRAF V600E mutated solid tumors or hematologic malignancies.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinated with Twinrix™ Adult following a two-dose schedule or Twinrix™ Junior following a three-dose schedule
For the long-term follow-up phase: To evaluate anti-HAV and anti-HBs antibody persistence at Years 11, 12, 13, 14 and 15 after the first vaccine dose of a two-dose Twinrix Adult or a three-dose Twinr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
11
Suivant